步長製藥(603858.SH):陝西步長與科貝源就鹽酸普萘洛爾口服溶液簽訂技術開發合同
格隆匯6月3日丨步長製藥(603858.SH)公佈,2021年5月13日,公司全資子公司山東丹紅、陝西步長製藥有限公司(以下簡稱“陝西步長”)與科貝源(北京)就上述協議簽訂《鹽酸普萘洛爾口服溶液(4.28mg/ml,120ml)技術開發合同三方協議》,山東丹紅將合同中未履行的合同內容轉由陝西步長承繼。
近日,陝西步長與科貝源(北京)就鹽酸普萘洛爾口服溶液(4.28mg/ml,120ml)簽訂《技術開發合同》,進一步明確雙方責任與義務,項目技術開發費用人民幣1360萬元。
公司按照“管理辦法”及NMPA等要求,結合該項目《審批意見通知件》中涉及的有關要求開展該項目研究,保證該項目與原研藥品質量和療效一致,最終使科貝源或其指定方獲得NMPA批准的該項目批准文號、繼而使該項目成功獲得再註冊。
公司指導科貝源在科貝源指定場地完成連續三批與原研藥品質量一致的商業化規模藥品製備。
本次簽訂技術開發合同有利於公司進一步優化產業佈局,有利於縮短藥品的研發週期,一定程度上節約了公司的研發成本,分攤研發風險,進一步保障了公司利益,保障項目的順利進行。本次技術開發合同不會對公司財務狀況和經營成果產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.